Breast cancers that lack expression of the ER, PR, and overexpression of HER2 are classified as triple negative and treated with cytotoxic chemotherapy due to lack of approved targeted therapy [15,16,17,18]. This evidence concerns the gene ERBB2 and breast cancer.